Welcome to our dedicated page for Adicet Bio news (Ticker: $ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adicet Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adicet Bio's position in the market.
Rhea-AI Summary
Adicet Bio, Inc. has announced a public offering of common stock and pre-funded warrants, with an expected gross proceeds of approximately $85.2 million. The offering aims to raise funds for the clinical stage biotechnology company's research and development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (ACET) has announced the commencement of an underwritten public offering of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is subject to market conditions and the company's shelf registration statement previously filed with the SEC. Jefferies and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) aims to expand the clinical development of ADI-001 into autoimmune diseases following the clearance of the Investigational New Drug Application (IND). The company plans to initiate a Phase 1 clinical study in 2Q 2024, focusing on mantle cell lymphoma (MCL) given favorable complete response (CR) rate, durability, and safety. They also expect to submit an IND for ADI-270 in renal cell carcinoma in 2Q 2024, with an updated cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.73%
Tags
News
Rhea-AI Summary
Adicet Bio, Inc. (ACET) to Host Conference Call and Webcast Presentation to Provide Update on Clinical Pipeline and Corporate Outlook
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.73%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award to a new employee, providing 84,000 non-qualified stock options at an exercise price of $1.89 per share. The options will vest over a four-year period, subject to the employee's continued employment. The award was granted outside of Adicet's stockholder-approved equity incentive plans pursuant to the Inducement Plan adopted by the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (ACET) announced encouraging observations from the pharmacokinetic and pharmacodynamic analyses of ADI-001 at the 65th ASH Annual Meeting. The data showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL), supporting ADI-001's potential as a best-in-class allogeneic CAR T platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
ACET: Adicet Bio Reports 3rd Quarter Financial Results and Operational Highlights, Initiates Phase 1 EXPAND Cohort for ADI-001 in Post CAR T LBCL, Prioritizes ADI-270 for Solid Tumor Applications
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) will present at the 2023 Jefferies London Healthcare Conference on November 14, 2023. The presentation will be available via live audio webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
-
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) has announced the acceptance of a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation will focus on the expansion, persistence, and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR Gamma Delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. The presentation will be given by Dr. Monica Moreno on December 10, 2023, from 6:00 - 8:00 p.m. PDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.85%
Tags
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) has granted an inducement award to a new employee, consisting of 5,000 non-qualified stock options. The exercise price is $1.32 per share, with vesting scheduled over a four-year period. The award was granted outside of Adicet's stockholder-approved equity incentive plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
Adicet Bio, Inc.
Nasdaq:ACET
ACET Rankings
ACET Stock Data
119.15M
49.05M
1.42%
67.94%
9.36%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
BOSTON
About ACET
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v